LONDON: Schroders Capital Global Innovation Trust plc announced its follow-on investment in Memo Therapeutics AG, a late clinical-stage biotech company based in Switzerland. The Company invested CHF 0.5 million (£0.4 million) in Memo’s Series C extension financing round, which raised CHF 20 million (£17 million) and was co-led by new investors, Ysios Capital and Kurma…
All posts tagged Memo Therapeutics AG
Schroders Capital Global Innovation Trust makes investment in Memo Therapeutics
LONDON: Schroders Capital Global Innovation Trust has made a commitment of CHF 0.9 million (£0.8 million) to Memo Therapeutics AG, a Switzerland-based clinical-stage biopharmaceutical company. The Company participated in Memo’s Series C financing round, which raised CHF 25 million and was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, GF…